Growth Metrics

Supernus Pharmaceuticals (SUPN) Short term Debt (2020 - 2025)

Supernus Pharmaceuticals has reported Short term Debt over the past 9 years, most recently at $31.1 million for Q4 2025.

  • Quarterly Short term Debt fell 34.41% to $31.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.1 million through Dec 2025, down 34.41% year-over-year, with the annual reading at $31.1 million for FY2025, 34.41% down from the prior year.
  • Short term Debt was $31.1 million for Q4 2025 at Supernus Pharmaceuticals, up from $11.2 million in the prior quarter.
  • Over five years, Short term Debt peaked at $401.4 million in Q3 2022 and troughed at $11.2 million in Q3 2025.
  • The 5-year median for Short term Debt is $45.4 million (2021), against an average of $56.9 million.
  • Year-over-year, Short term Debt soared 1603.17% in 2022 and then tumbled 88.57% in 2023.
  • A 5-year view of Short term Debt shows it stood at $44.8 million in 2021, then crashed by 52.9% to $21.1 million in 2022, then soared by 146.54% to $52.1 million in 2023, then dropped by 9.08% to $47.3 million in 2024, then plummeted by 34.41% to $31.1 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Short term Debt are $31.1 million (Q4 2025), $11.2 million (Q3 2025), and $30.0 million (Q1 2025).